var data={"title":"Ganciclovir (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ganciclovir (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389597?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ganciclovir-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ganciclovir (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=ganciclovir-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ganciclovir (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106920\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hematologic toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported with ganciclovir.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Impairment of fertility:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, ganciclovir has the potential to cause birth defects in humans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mutagenesis and carcinogenesis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Based on animal data, ganciclovir has the potential to cause cancer in humans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106925\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cytovene</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106926\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cytovene</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501471\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442566\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">IV: <b>Congenital CMV (symptomatic; CNS-disease); treatment (independent of HIV status):</b> 6 mg/kg/dose every 12 hours for 6 weeks; if neonate diagnosed as HIV-positive, a longer duration of therapy may be considered (CDC, 2009; Redbook, 2009) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503504\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ganciclovir-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ganciclovir (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Congenital CMV (symptomatic; CNS-disease); treatment (independent of HIV status): 6 mg/kg/dose  every 12 hours for 6 weeks; if neonate diagnosed as HIV-positive a longer duration of therapy may be considered (CDC, 2009; Redbook, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS infection, treatment (HIV-exposed/-positive): Infants and Children: 5 mg/kg/dose every 12 hours plus foscarnet; continue until symptoms improve, followed by chronic suppression (CDC, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Disseminated disease and retinitis, treatment:  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 months and Children: 5 mg/kg/dose every 12 hours for 14-21 days; may be increased to 7.5 mg/kg/dose every 12 hours (CDC, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: Manufacturer&rsquo;s labeling: 5 mg/kg/dose every 12 hours for 14-21 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge; 3 months and Children: 5 mg/kg/dose as a single daily dose for 5-7 days/week (CDC, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: Manufacturer&rsquo;s labeling: 5 mg/kg/dose as a single daily dose for 7 days/week or 6 mg/kg/dose for 5 days/week </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Secondary prevention in HIV-exposed/-infected patients: Infants and Children: 5 mg/kg/dose once daily (CDC, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention in transplant recipients: Children and Adults: Initial: 5 mg/kg/dose  every 12 hours for 1-2 weeks, followed by 5 mg/kg/dose once daily 7 days/week or 6 mg/kg/dose once daily 5 days/week for 100 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention in lung/heart-lung transplant patients (CMV-positive donor with CMV-positive recipient): Children and Adults: 6 mg/kg/dose once daily for 28 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Other CMV infections: Children and Adults: Initial: 5 mg/kg/dose every 12 hours for 14-21 days; maintenance therapy: 5 mg/kg/dose once daily for 7 days/week or 6 mg/kg/dose once daily for 5 days/week </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella zoster; progressive outer retinal necrosis:</b> Infants, Children, Adolescents, and Adults: 5 mg/kg/dose every 12 hours plus systemic foscarnet and intravitreal ganciclovir or foscarnet (CDC, 2009; Kaplan, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing interval in renal impairment:</b>  Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50-69 mL/minute: Administer 2.5 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 25-49 mL/minute: Administer 2.5 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10-24 mL/minute: Administer 1.25 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer 1.25 mg/kg/dose 3 times/week following hemodialysis </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50-69 mL/minute: Administer 2.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 25-49 mL/minute: Administer 1.25 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10-24 mL/minute: Administer 0.625 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer 0.625 mg/kg/dose 3 times/week following hemodialysis </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50%): CMV Infection: IV: Induction: 1.25 mg/kg every 48-72 hours; Maintenance: 0.625 mg/kg every 48-72 hours. <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): Dose as for CrCl &lt;10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment: CMV infection:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH: IV: Induction: 2.5 mg/kg every 24 hours; Maintenance: 1.25 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHD/CVVHDF: IV: Induction: 2.5 mg/kg every 12 hours; Maintenance: 2.5 mg/kg every 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112462\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Infants, Children and Adolescents: There are no specific pediatric recommendations; based on experience in adult patients, dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112463\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107009\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=ganciclovir-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ganciclovir (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV retinitis (immunocompromised patients):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction therapy: IV: 5 mg/kg/dose every 12 hours for 14 to 21 days followed by maintenance therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance therapy: IV: 5 mg/kg/dose once daily for 7 days/week or 6 mg/kg/dose once daily for 5 days/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing (HHS [OI adult 2017]): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peripheral lesions (alternative agent): IV: Induction: 5 mg/kg/dose every 12 hours for 14 to 21 days followed by chronic maintenance (secondary prophylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate sight-threatening lesions (adjacent to the optic nerve or fovea): Intravitreal injection (off-label route): Induction therapy: 2 mg of an extemporaneously prepared solution administered as intravitreal injections for 1 to 4 doses over a period of 7 to 10 days; administer with a concomitant systemically administered agent (oral valganciclovir preferred).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV disease prophylaxis in transplant patients:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction therapy: 5 mg/kg/dose every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance therapy: 5 mg/kg/dose once daily for 7 days/week or 6 mg/kg/dose once daily for 5 days/week; duration is dependent on clinical condition and degree of immunosuppression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematopoietic cell transplant recipients (allogeneic): 5 mg/kg/dose every 12 hours for 5 to 7 days, then 5 mg/kg/dose every 24 hours until day 100 post-transplant (Tomblyn 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solid organ transplant recipients: 5 mg/kg/dose every 24 hours; duration of prophylaxis is dependent on type of transplant, as well as donor and recipient CMV serostatus (Kotton 2013).</p>\n    <p style=\"text-indent:0em;\">\n      <b>CMV disease, preemptive therapy (hematopoietic cell transplant recipients) (off-label use) (Tomblyn 2009): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&lt;100 days post-transplant:</i> 5 mg/kg/dose every 12 hours for 7 days (autologous transplant) or 7 to 14 days (allogenic transplant), then 5 mg/kg/dose every 24 hours for 1 to 2 weeks or until the indicator test is negative (minimum total induction and maintenance treatment is 2 weeks when 14 days of twice daily is used and 3 weeks when a 7-day induction course is used).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&gt;100 days post-transplant:</i> 5 mg/kg/dose every 12 hours for 7 to 14 days, then 5 mg/kg/dose every 24 hours for 1 to 2 weeks or until the indicator test is negative.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV disease, treatment (solid organ transplant recipients) (off-label use): </b>IV: 5 mg/kg/dose every 12 hours until 1 or 2 consecutive undetectable CMV viral load samples are obtained (minimum treatment course: 2 weeks) (Kotton 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i> UL97 mutation for &lt;5x ganciclovir EC50:</i> 10 mg/kg/dose every 12 hours (Kotton 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Ganciclovir-resistant strains: </i>5 mg/kg/dose every 24 hours in combination with daily foscarnet and monthly CMV hyperimmunoglobulin (Mylonakis 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV esophagitis or colitis in HIV-infected patients (off-label use):</b> IV: 5 mg/kg/dose every 12 hours, then change to oral valganciclovir therapy once oral therapy is tolerated; total duration of therapy: 21 to 42 days or until symptom resolution (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV neurological disease in HIV-infected patients (off-label use):</b> IV: 5 mg/kg/dose every 12 hours plus foscarnet until symptoms improve (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV retinitis, chronic maintenance (secondary prophylaxis) in HIV-infected patients (off-label use; alternative agent):</b> IV: 5 mg/kg/dose 5 to 7 times weekly; continue until sustained CD4 count &gt;100 cells/mm<sup>3</sup> in response to ART for 3 to 6 months; discontinue only after consultation with an ophthalmologist) (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella-zoster: Acute retinal necrosis (ARN) in HIV-infected patients (off-label use): </b> Intravitreal injection (off-label route): 2 mg of an extemporaneously prepared solution administered as an intravitreal injection twice weekly for 1 to 2 doses in combination with IV acyclovir for 10 to 14 days, followed by valacyclovir for 6 weeks (HHS [OI adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella-zoster: Progressive outer retinal necrosis in HIV-infected patients (off-label use): </b> IV: 5 mg/kg/dose every 12 hours (with or without IV foscarnet) <b>plus</b> intravitreal ganciclovir and/or intravitreal foscarnet (HHS [OI adult 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990524\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Renally adjusted dose recommendations are based on an induction dose of 5 mg/kg/dose every 12 hours and a maintenance dose of 5 mg/kg/dose every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV (Induction): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;70 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 50 to 69 mL/minute: Administer 2.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 25 to 49 mL/minute: Administer 2.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 24 mL/minute: Administer 1.25 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer 1.25 mg/kg/dose 3 times/week following hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV (Maintenance): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;70 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 50 to 69 mL/minute: Administer 2.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 25 to 49 mL/minute: Administer 1.25 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 24 mL/minute: Administer 0.625 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer 0.625 mg/kg/dose 3 times/week following hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50%): CMV Infection: IV: Induction: 1.25 mg/kg every 48 to 72 hours; Maintenance: 0.625 mg/kg every 48 to 72 hours. <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis (PD): Dose as for CrCl &lt;10 mL/minute (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005):  Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment: CMV Infection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH: IV: Induction: 2.5 mg/kg every 24 hours; Maintenance: 1.25 mg/kg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVHD/CVVHDF: IV: Induction: 2.5 mg/kg every 12 hours; Maintenance: 2.5 mg/kg every 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987831\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8107058\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/250 mL (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytovene: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106928\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503524\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Follow same precautions utilized with antineoplastic agents when preparing and administering ganciclovir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer by slow IV infusion over at least 1 hour; too rapid infusion can cause increased toxicity and excessive plasma levels. Flush line well with NS before and after administration. Do not administer IM or SubQ; due to high pH, may cause severe tissue irritation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132599\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) when compounding. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106974\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials and premixed solution bags at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Reconstituted solution in the vial is stable at room temperature for 12 hours; do not refrigerate or freeze. Diluted solutions for infusion should be refrigerated and used within 24 hours of preparation; do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503162\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with AIDS (FDA approved in adults); prevention of CMV disease in transplant recipients at risk for CMV (FDA approved in adults); has also been used in CMV GI infections and pneumonitis; ganciclovir also has antiviral activity against herpes simplex virus types 1 and 2 </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106922\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytovene may be confused with Cytosar, Cytosar-U</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ganciclovir may be confused with acyclovir </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106966\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, diarrhea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia, neutropenia (ANC &lt;500/mm<sup>3</sup>), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Retinal detachment (relationship to ganciclovir not established)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia, brain disease, bronchospasm, cardiac arrhythmia, cataract, cholestasis, coma, dyspnea, edema, eosinophilia, exfoliative dermatitis, extrapyramidal reaction, hemorrhage, hepatic failure, hepatitis, hypersensitivity reaction (including anaphylaxis), pancreatitis, pancytopenia, psychosis, pulmonary fibrosis, renal failure, rhabdomyolysis, seizure, SIADH (syndrome of inappropriate antidiuretic hormone secretion), Stevens-Johnson syndrome, torsades de pointes, urticaria, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106951\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ganciclovir, valganciclovir, acyclovir, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106952\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic/teratogenic: <b>[US Boxed Warning]: May cause temporary or permanent inhibition of spermatogenesis and suppression of fertility; has the potential to cause birth defects and cancers in humans.</b> Due to its teratogenic potential, females should undergo pregnancy testing prior to initiation and use effective contraception during treatment and for 30 days after; males should use barrier contraception during treatment and for 90 days after.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: <b>[US Boxed Warning]: Granulocytopenia (neutropenia), anemia, thrombocytopenia, and pancytopenia may occur. </b>Neutropenia usually occurs during the first 1 to 2 weeks of treatment but may occur at any time; cell counts usually begin to recover within 3 to 7 days of treatment discontinuation. Colony-stimulating factors have been shown to increase neutrophil and white blood cell counts in patients receiving ganciclovir. Use with caution in patients with pre-existing cytopenias and in patients receiving myelosuppressive drugs or irradiation. Frequently monitor complete blood count with differential and platelet counts, especially in patients with renal impairment and in patients who have previously experienced drug-induced leukopenia or who have neutrophil counts &lt;1,000 cells/mm<sup>3 </sup>at the beginning of treatment. Ganciclovir is not recommended in patients with an absolute neutrophil count (ANC) &lt;500 cells/mm<sup>3</sup>, hemoglobin &lt;8 g/dL, or platelet count &lt;25,000 cells/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Increased serum creatinine levels have been reported in elderly patients and transplant patients receiving concomitant nephrotoxic medications (eg, cyclosporine, amphotericin B). Monitor renal function during therapy, especially in elderly patients and those receiving concomitant nephrotoxic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Increased serum creatinine levels have been reported; use with caution and closely monitor serum creatinine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Ensure patients are adequately hydrated. Avoid rapid infusion. Phlebitis and/or pain may occur at injection site despite adequate dilution; infuse solution into veins with adequate blood flow.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299387\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106969\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15994&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Ganciclovir-Valganciclovir may increase the serum concentration of Didanosine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased.  Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Zidovudine. Specifically, hematologic toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106947\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Based on animal data, use may suppress fertility in females, inhibit spermatogenesis in males, and cause birth defects if used in pregnant women. </b>Ganciclovir crosses the placenta. Female patients should undergo pregnancy testing prior to initiation and use effective contraception during and for at least 30 days after therapy. Male patients should use a barrier contraceptive during and for at least 90 days after therapy. The inhibition of spermatogenesis may be temporary or permanent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503525\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, urine output, serum creatinine, ophthalmologic exams, liver enzyme tests, blood pressure, urinalysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106992\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8106994\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Children 9 months to 12 years: 0.64 &plusmn; 0.22 L/kg; Adults: 0.74 &plusmn; 0.15 L/kg; widely to all tissues including CSF and ocular tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 1% to 2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates 2 to 49 days of age: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 9 months to 12 years: 2.4 &plusmn; 0.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Mean: IV: 3.5 &plusmn; 0.9 hours; Oral: 4.8 &plusmn; 0.9 hours; CrCl &lt;25 mL/minute: 10.7 &plusmn; 5.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 99% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196094\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: Clearance is decreased and half-life is prolonged.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501474\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of 1 g: 4 mEq</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322180\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ganciclovir Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/250 mL (250 mL): $96.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cytovene Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $142.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ganciclovir Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $86.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390229\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ciganclor (PY, UY);</li>\n      <li>Cymevan (FR);</li>\n      <li>Cymeven (CY);</li>\n      <li>Cymevene (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CZ, DK, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, HK, HN, HR, IL, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LK, LR, LT, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PL, PY, QA, RO, SA, SC, SD, SE, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, VE, VN, YE, ZM, ZW);</li>\n      <li>Ganguard (IN);</li>\n      <li>Neagel (AR);</li>\n      <li>Tsymeven (UA);</li>\n      <li>Virgan (AR, BE, CZ, DE, FR, GB, HK, KR, PH, PT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amir J, Wolf DG, and Levy I, &quot;Treatment of Symptomatic Congenital Cytomegalovirus Infection With Intravenous Ganciclovir Followed by Long-Term Oral Valganciclovir,&quot; <i>Eur J Pediatr</i>, 2010, 169(9):1061-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/20232081/pubmed\" target=\"_blank\" id=\"20232081\">20232081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-4):1-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/19357635/pubmed\" target=\"_blank\" id=\"19357635\">19357635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fletcher C, Sawchuk R, Chinnock B, et al, &ldquo;Human Pharmacokinetics of the Antiviral Drug DHPG,&rdquo; <i>Clin Pharmacol Ther</i>, 1986, 40(3):281-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/3017630/pubmed\" target=\"_blank\" id=\"3017630\">3017630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodrich JM, Bowden RA, Fisher L, et al, &quot;Ganciclovir Prophylaxis to Prevent Cytomegalovirus Disease After Allogeneic Marrow Transplant,&quot; <i>Ann Intern Med</i>, 1993, 118(3):173-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/8380242/pubmed\" target=\"_blank\" id=\"8380242\">8380242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gudnason T, Belani KK, and Balfour HH Jr, &ldquo;Ganciclovir Treatment of Cytomegalovirus Disease in Immunocompromised Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(7):436-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/2547191/pubmed\" target=\"_blank\" id=\"2547191\">2547191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merigan TC, Renlund DG, Keay S, et al, &quot;A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease After Heart Transplantation,&quot; <i>N Engl J Med</i>, 1992, 326(18):1182-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/1313549/pubmed\" target=\"_blank\" id=\"1313549\">1313549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2009 Report of the Committee on Infectious Diseases</i>, &quot;Group B Streptococcal Infections,&quot; 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schleiss MR, &quot;Antiviral Therapy of Congenital Cytomegalovirus Infection,&quot; <i>Semin Pediatr Infect Dis</i>, 2005, 16(1):50-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/15685150/pubmed\" target=\"_blank\" id=\"15685150\">15685150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41:1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ganciclovir-systemic-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15994 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8106920\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8106925\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8106926\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10501471\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442566\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F10503504\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112462\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112463\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8107009\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990524\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987831\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8107058\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8106928\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10503524\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132599\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8106974\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10503162\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8106922\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8106966\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8106951\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8106952\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299387\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8106969\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8106947\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10503525\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8106992\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8106994\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196094\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10501474\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322180\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390229\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15994|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ganciclovir-systemic-drug-information\" class=\"drug drug_general\">Ganciclovir (systemic): Drug information</a></li><li><a href=\"topic.htm?path=ganciclovir-systemic-patient-drug-information\" class=\"drug drug_patient\">Ganciclovir (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}